版本:
中国

BRIEF-U.S. FDA grants priority review status to Ultragenyx metabolic disorder drug

May 23 Ultragenyx Pharmaceutical Inc-

* Ultragenyx announces recombinant human beta-glucuronidase biologics license application and marketing authorization application filed and accepted for review; FDA grants priority review status

* Ultragenyx Pharmaceutical Inc - prescription drug user fee act (pdufa) goal date for a decision is november 16, 2017

* Ultragenyx Pharmaceutical Inc - opinion from committee for medicinal products for human use (chmp) is expected in first half of 2018 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐